| Identification | Back Directory | [Name]
2-Pyridinamine, 3-(difluoromethoxy)-5-[2-(3,3-difluoro-1-pyrrolidinyl)-6-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-4-pyrimidinyl]- | [CAS]
1637394-01-4 | [Synonyms]
GDC-0134
2-Pyridinamine, 3-(difluoromethoxy)-5-[2-(3,3-difluoro-1-pyrrolidinyl)-6-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-4-pyrimidinyl]- | [Molecular Formula]
C19H20F4N6O2 | [MOL File]
1637394-01-4.mol | [Molecular Weight]
440.39 |
| Hazard Information | Back Directory | [Uses]
GDC-0134 is a potent, selective, orally active, brain-penetrant dual leucine zipper kinase (DLK) inhibitor. GDC-0134 blocks DLK activity in cellular assays and in animal models of neuronal injury. GDC-0134 can be used for the study of amyotrophic lateral sclerosis (ALS)[1]. | [References]
[1] Jonathan S Katz, et al. A Phase 1 study of GDC-0134, a dual leucine zipper kinase inhibitor, in ALS. Ann Clin Transl Neurol. 2022 Jan;9(1):50-66. DOI:10.1002/acn3.51491 |
|
|